Any news on advancements in osteoarthritis disease treatments or medication

On 13 July 2026, the FDA granted Regenerative Medicine Advanced Therapy (RMAT) designation to Allocetra™, an immunotherapy for age-related knee osteoarthritis, which may expedite its development and review. Additionally, recent reports confirm that NICE continues to exclude the injectable hydrogel Arthrosamid from routine NHS use due to insufficient evidence, while a new PDUFA target date of 24 April 2027 has been set for the regenerative treatment ReNu.

• Allocetra FDA RMAT Designation: On 13 July 2026, the FDA granted RMAT designation to Enlivex's Allocetra™ for treating symptomatic knee osteoarthritis in patients aged 64 and older, following successful Phase I/IIa trial results.
• NICE Status for Arthrosamid: As of July 2026, the National Institute for Health and Care Excellence (NICE) maintains that Arthrosamid is not recommended for routine NHS use, despite its availability in private clinics, citing a lack of long-term evidence.
• ReNu FDA Review Timeline: Following the acceptance of its Biologics License Application (BLA) in early July 2026, the FDA has assigned a PDUFA target action date of 24 April 2027 for the regenerative knee treatment ReNu. 📅 Calendar file (.ics) ReNu FDA PDUFA Target Date April 24, 2027
• Stanford Cartilage Research News: On 13 July 2026, medical reports highlighted a Stanford University breakthrough involving the 15-PGDH protein, which successfully triggered cartilage growth in human tissue samples, though it remains in the research stage.

Between 10 and 12 July 2026, the first cannabis-based medication for chronic pain, Exilby, received marketing authorization in Europe, providing a new systemic treatment option for managing osteoarthritis symptoms. While no new NHS or NICE approvals were announced in this window, the FDA recently accepted a Biologics License Application for ReNu, a regenerative knee treatment, and new clinical data for Nexsphere-F demonstrated significant pain reduction through genicular artery embolization.

• Exilby Marketing Authorization: On 11 July 2026, Exilby was authorized in Germany and Austria as the first cannabis-based medication for chronic pain, with a commercial launch expected in August 2026. (August 1, 2026) 📅 Calendar file (.ics) Exilby Chronic Pain Medication Launch August 1, 2026
• ReNu FDA BLA Acceptance: In July 2026, the FDA accepted the Biologics License Application for ReNu, a cryopreserved amniotic suspension allograft for knee osteoarthritis, setting a target action date of 24 April 2027. 📅 Calendar file (.ics) FDA PDUFA Date for ReNu April 24, 2027
• Nexsphere-F Clinical Success: On 6 July 2026, a prospective study published in Radiology reported that Nexsphere-F achieved a 57% reduction in knee osteoarthritis pain via genicular artery embolization.
• NHS Funding Status: As of July 2026, NHS guidelines (NICE NG226) continue to routinely fund only corticosteroid injections for knee osteoarthritis, while hyaluronic acid is contraindicated and treatments like Arthrosamid remain outside routine commissioning.

On 8 and 9 July 2026, significant updates in joint preservation and regenerative medicine were announced, including new clinical data showing that the BEAR Implant helps reduce the risk of post-traumatic osteoarthritis. Additionally, Australian firm Integrant launched a new phase for its AI-driven biologics platform focused on cartilage regeneration, while the FDA approved a label expansion for guselkumab to inhibit structural joint damage in related inflammatory conditions.

• BEAR Implant Registry Outcomes: On 9 July 2026, two-year data from the Bridge Registry presented at the AOSSM Annual Meeting highlighted that the BEAR Implant for ACL restoration significantly reduces the incidence of post-traumatic osteoarthritis.
• Integrant AI-Biologics Platform: On 9 July 2026, Integrant Pty Ltd announced a new capital raise to support its midstage biologics program, which utilizes an AI-driven platform to regenerate cartilage and preserve joint function.
• FDA Label Expansion for Guselkumab: On 8 July 2026, the FDA approved a label expansion for guselkumab (Tremfya) to include the inhibition of structural joint damage progression, marking a key advancement in treating inflammatory joint destruction.

Between 6 and 7 July 2026, several major advancements in osteoarthritis treatment were announced, including the publication of clinical results for the Nexsphere-F artery-blocking device and the discovery of anti-inflammatory benefits in a new weight-loss drug. Additionally, the FDA accepted a Biologics License Application for ReNu, a regenerative amniotic suspension, marking a significant step toward its potential approval for symptomatic knee osteoarthritis.

• Nexsphere-F Clinical Publication: On 6 July 2026, the journal Radiology published results for Nexsphere-F, a fast-resorbable microsphere used in genicular artery embolization (GAE), which achieved a 57% reduction in knee pain at 12 months.
• Retatrutide Trial Breakthrough: On 7 July 2026, Eli Lilly announced that its triple-hormone weight-loss drug, retatrutide, significantly reduced knee pain and inflammation in a 68-week trial of adults with obesity and osteoarthritis. 📅 Calendar file (.ics) Retatrutide Osteoarthritis Trial Results Announcement July 7, 2026
• FDA Acceptance of ReNu BLA: On 6 July 2026, Organogenesis announced that the FDA accepted its Biologics License Application (BLA) for ReNu, a cryopreserved amniotic suspension for managing symptomatic knee osteoarthritis.
• NICE Guidance on Arthrosamid: As of July 2026, NICE continues to advise against the routine use of Arthrosamid hydrogel injections on the NHS due to insufficient evidence, despite its promotion in private clinics.